Ocifisertib

Overview

CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a K i and an IC 50 of 0.26 nM and 2.8 nM, respectively.

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Polo-like Kinase (PLK) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-12300
• CAS No.: 1338806-73-7
• Molecular Formula: C33H34N4O3
• Molecular Weight: 534.65
• Purity: 99.78%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution
• Availability: In-stock

Source

Original product source